RSS feed

Publications by Øyvind Melien

36 publications found

Original articles

Pisana A, Wettermark B, Kurdi A, Tubic B, Pontes C, Zara C, Van Ganse E, Petrova G, Mardare I, Fürst J, Roig-Izquierdo M, Melien O, Bonanno PV, Banzi R, Marković-Peković V, Mitkova Z, Godman B (2022)
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries
Front Pharmacol, 13, 873556
DOI 10.3389/fphar.2022.873556, PubMed 35865969

Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, Kalemeera F, Hoxha I, Nachtnebel A, Sauermann R, Hinteregger M, Marković-Peković V, Tubic B, Petrova G, Tachkov K, Slabý J, Nejezchlebova R, Krulichová IS, Laius O, Selke G, Langner I, Harsanyi A, Inotai A, Jakupi A, Henkuzens S et al. (2021)
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
Biomed Res Int, 2021, 9996193
DOI 10.1155/2021/9996193, PubMed 34676266

Godman B, Hill A, Simoens S, Selke G, Selke Krulichová I, Zampirolli Dias C, Martin AP, Oortwijn W, Timoney A, Gustafsson LL, Voncina L, Kwon HY, Gulbinovic J, Gotham D, Wale J, Cristina Da Silva W, Bochenek T, Allocati E, Kurdi A, Ogunleye OO, Meyer JC, Hoxha I, Malaj A, Hierländer C, Sauermann R et al. (2021)
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Expert Rev Pharmacoecon Outcomes Res, 21 (4), 527-540
DOI 10.1080/14737167.2021.1884546, PubMed 33535841

Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, Stockinger S, Mörtenhuber S, Dimitrova M, Tachkov K, Vončina L, Palčevski VV, Achniotou G, Slabý J, Popelková L, Kohoutová K, Bartels D, Laius O, Martikainen JE, Selke GW, Kourafalos V, Magnússon E, Einarsdóttir R, Adams R, Joppi R et al. (2021)
The Expiry of Humira^® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Front Pharmacol, 11, 591134
DOI 10.3389/fphar.2020.591134, PubMed 33519450

Leyens L, Richer É, Melien Ø, Ballensiefen W, Brand A (2015)
Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine
Public Health Genomics, 18 (5), 249-59
DOI 10.1159/000437137, PubMed 26316202

Kvehaugen AS, Melien Ø, Holmen OL, Laivuori H, Dechend R, Staff AC (2014)
Hypertension after preeclampsia and relation to the C1114G polymorphism (rs4606) in RGS2: data from the Norwegian HUNT2 study
BMC Med Genet, 15, 28
DOI 10.1186/1471-2350-15-28, PubMed 24593135

Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, Malmström RE, Vogler S, Godman B, Gustafsson LL (2013)
Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations
Eur J Clin Pharmacol, 69 Suppl 1, 73-8
DOI 10.1007/s00228-013-1497-5, PubMed 23640191

Kvehaugen AS, Melien Ø, Holmen OL, Laivuori H, Dechend R, Staff AC (2013)
PP084. Hypertension after preeclampsia in women with C1114G polymorphism in rgs2 (the regulator of g protein signaling 2)
Pregnancy Hypertens, 3 (2), 98
DOI 10.1016/j.preghy.2013.04.109, PubMed 26105937

Elsais A, Popperud TH, Melien Ø, Kerty E (2013)
[Drugs that may trigger or exacerbate myasthenia gravis]
Tidsskr Nor Laegeforen, 133 (3), 296-9
DOI 10.4045/tidsskr.12.0624, PubMed 23381166

Kvehaugen AS, Melien O, Holmen OL, Laivuori H, Oian P, Andersgaard AB, Dechend R, Staff AC (2013)
Single nucleotide polymorphisms in G protein signaling pathway genes in preeclampsia
Hypertension, 61 (3), 655-61
DOI 10.1161/HYPERTENSIONAHA.111.00331, PubMed 23339167

Opdal SH, Melien O, Hynnekleiv T, Rognum TO (2011)
The brain-derived neutrophic factor val66met polymorphism and sudden unexpected infant death
Acta Paediatr, 100 (1), 86-9
DOI 10.1111/j.1651-2227.2010.01960.x, PubMed 20653606

Romundstad S, Melien O, Holmen J (2010)
The G protein β3 subunit C825T polymorphism is associated with microalbuminuria in hypertensive women and cardiovascular disease in hypertensive men
Am J Hypertens, 23 (10), 1114-20
DOI 10.1038/ajh.2010.131, PubMed 20577224

Holmen OL, Romundstad S, Melien O (2010)
Association between the G protein β3 subunit C825T polymorphism and the occurrence of cardiovascular disease in hypertensives: The Nord-Trøndelag Health Study (HUNT)
Am J Hypertens, 23 (10), 1121-7
DOI 10.1038/ajh.2010.121, PubMed 20539277

Osberg S, Melien O, Taubøll E, Gjerstad L, Norwegian GenEpA Group (2008)
G protein beta3 subunit C825T polymorphism modifies the presentation of temporal lobe epilepsy
Acta Neurol Scand Suppl, 188, 62-6
DOI 10.1111/j.1600-0404.2008.01034.x, PubMed 18439224

Hauge Opdal S, Melien Ø, Rootwelt H, Vege A, Arnestad M, Ole Rognum T (2006)
The G protein beta3 subunit 825C allele is associated with sudden infant death due to infection
Acta Paediatr, 95 (9), 1129-32
DOI 10.1080/08035250600580529, PubMed 16938762

Melien Ø, Skaali T, Myhr K, Brørs O (2005)
Venlafaxine and asthma
Nord J Psychiatry, 59 (6), 538-40
DOI 10.1080/08039480500363595, PubMed 16316911

Jensen J, Sharikabad MN, Østbye KM, Melien Ø, Brørs O (2003)
Evidence that nitroprusside stimulates glucose uptake in isolated rat cardiomyocytes via mitogen-activated protein kinase
Arch Physiol Biochem, 111 (3), 239-45
DOI 10.1076/apab.111.3.239.23463, PubMed 14972746

Melien Ø, Johansen PW, Westergren T, Rugstad HE (2003)
[Vitamin K in food and the effect of warfarin]
Tidsskr Nor Laegeforen, 123 (13-14), 1862-3
PubMed 12830268

Melien O, Nilssen LS, Dajani OF, Sand KL, Iversen JG, Sandnes DL, Christoffersen T (2002)
Ca2+-mediated activation of ERK in hepatocytes by norepinephrine and prostaglandin F2 alpha: role of calmodulin and Src kinases
BMC Cell Biol, 3, 5
DOI 10.1186/1471-2121-3-5, PubMed 11914123

Melien O, Christoffersen T, Sioud M (2001)
Evidence for the involvement of Gi2 in activation of extracellular signal-regulated kinases in hepatocytes
BMC Cell Biol, 2, 13
DOI 10.1186/1471-2121-2-13, PubMed 11495629

Melien O, Sandnes D, Johansen EJ, Christoffersen T (2000)
Effects of pertussis toxin on extracellular signal-regulated kinase activation in hepatocytes by hormones and receptor-independent agents: evidence suggesting a stimulatory role of G(i) proteins at a level distal to receptor coupling
J Cell Physiol, 184 (1), 27-36
DOI 10.1002/(SICI)1097-4652(200007)184:1<27::AID-JCP3>3.0.CO;2-Q, PubMed 10825231

Dajani OF, Sandnes D, Melien O, Rezvani F, Nilssen LS, Thoresen GH, Christoffersen T (1999)
Role of diacylglycerol (DAG) in hormonal induction of S phase in hepatocytes: the DAG-dependent protein kinase C pathway is not activated by epidermal growth factor (EGF), but is involved in mediating the enhancement of responsiveness to EGF by vasopressin, angiotensin II, and norepinephrine
J Cell Physiol, 180 (2), 203-14
DOI 10.1002/(SICI)1097-4652(199908)180:2<203::AID-JCP8>3.0.CO;2-T, PubMed 10395290

Melien O, Thoresen GH, Sandnes D, Ostby E, Christoffersen T (1998)
Activation of p42/p44 mitogen-activated protein kinase by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2alpha in hepatocytes is sustained, and like the effect of epidermal growth factor, mediated through pertussis toxin-sensitive mechanisms
J Cell Physiol, 175 (3), 348-58
DOI 10.1002/(SICI)1097-4652(199806)175:3<348::AID-JCP13>3.0.CO;2-1, PubMed 9572480

Melien O, Winsnes R, Refsnes M, Gladhaug IP, Christoffersen T (1988)
Pertussis toxin abolishes the inhibitory effects of prostaglandins E1, E2, I2 and F2 alpha on hormone-induced cAMP accumulation in cultured hepatocytes
Eur J Biochem, 172 (2), 293-7
DOI 10.1111/j.1432-1033.1988.tb13886.x, PubMed 2832160

Refsnes M, Sandnes D, Melien O, Sand TE, Jacobsen S, Christoffersen T (1983)
Mechanisms for the emergence of catecholamine-sensitive adenylate cyclase and beta-adrenergic receptors in cultured hepatocytes. Dependence on protein and RNA synthesis and suppression by isoproterenol
FEBS Lett, 164 (2), 291-8
DOI 10.1016/0014-5793(83)80304-4, PubMed 6197322

Review articles

Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe CC, Ferrario A, Bosselli S, Hill A, Martin AP, Simoens S, Kurdi A, Gad M, Gulbinovič J, Timoney A, Bochenek T, Salem A, Hoxha I, Sauermann R, Massele A, Guerra AA, Petrova G, Mitkova Z, Achniotou G, Laius O, Sermet C et al. (2018)
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
Front Public Health, 6, 328
DOI 10.3389/fpubh.2018.00328, PubMed 30568938

Vella Bonanno P, Ermisch M, Godman B, Martin AP, Van Den Bergh J, Bezmelnitsyna L, Bucsics A, Arickx F, Bybau A, Bochenek T, van de Casteele M, Diogene E, Eriksson I, Fürst J, Gad M, Greičiūtė-Kuprijanov I, van der Graaff M, Gulbinovic J, Jones J, Joppi R, Kalaba M, Laius O, Langner I, Mardare I, Markovic-Pekovic V et al. (2017)
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
Front Pharmacol, 8, 497
DOI 10.3389/fphar.2017.00497, PubMed 28878667

Sioud M, Melien O (2007)
Treatment options and individualized medicine
Methods Mol Biol, 361, 327-40
DOI 10.1385/1-59745-208-4:327, PubMed 17172721

Melien O (2007)
Heterotrimeric G proteins and disease
Methods Mol Biol, 361, 119-44
DOI 10.1385/1-59745-208-4:119, PubMed 17172709

Other articles

Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, Kalemeera F, Hoxha I, Nachtnebel A, Sauermann R, Hinteregger M, Marković-Peković V, Tubic B, Petrova G, Tachkov K, Slabý J, Nejezchlebova R, Krulichová IS, Laius O, Selke G, Langner I, Harsanyi A, Inotai A, Jakupi A, Henkuzens S et al. (2023)
Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications"
Biomed Res Int, 2023, 9757348
DOI 10.1155/2023/9757348, PubMed 37065720

EU-Response investigators group, Diallo A, Trøseid M, Simensen VC, Boston A, Demotes J, Olsen IC, Chung F, Paiva JA, Hites M, Ader F, Arribas JR, Baratt-Due A, Melien Ø, Tacconelli E, Staub T, Greil R, Tsiodras S, Briel M, Esperou H, Mentré F, Eustace J, Saillard J, Delmas C, LeMestre S et al. (2021)
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group
Clin Microbiol Infect, 28 (1), 1-5
DOI 10.1016/j.cmi.2021.10.011, PubMed 34763056

Tummers M, Kværner K, Sampietro-Colom L, Siebert M, Krahn M, Melien Ø, Hamerlijnck D, Abrishami P, Grutters J (2020)
On the integration of early health technology assessment in the innovation process: reflections from five stakeholders
Int J Technol Assess Health Care, 36 (5), 481-485
DOI 10.1017/S0266462320000756, PubMed 33109280

Hulstaert F, Ruether A, Demotes J, Melien Ø (2020)
Closing the cycle of innovation in healthcare in Europe
Int J Technol Assess Health Care, 36 (2), 75-79
DOI 10.1017/S0266462319003532, PubMed 31948497

Siegfried N, Steinhausen K, Ren J, Cazap E, Melien O, Subgroup Education, Training, Infrastructure and Patient Involvement, OECD GSF Working Group (2012)
Global core competencies for clinical trials
Lancet, 380 (9843), 728
DOI 10.1016/S0140-6736(12)61403-2, PubMed 22920747

Theses

Melien Ø (2000)
G proteins and signal transduction in hepatocytes with particular reference to mechanisms of activation of extracellular-signal regulated kinases
Department of Pharmacology, Faculty of Medicine, University of Oslo, [Oslo], 1 b. (flere pag.)
BIBSYS 010620818, ISBN 82-7633-151-3

Melien Ø (1983)
Studier av adenylat cyklase aktivitet fra dyrkede leverceller
Ø. Melien, Oslo, 125 s.
BIBSYS 961297395